Pharmacological BACE Inhibition Improves Axonal Regeneration in Nerve Injury and Disease Models
Tóm tắt
While the peripheral nervous system is able to repair itself following injury and disease, recovery is often slow and incomplete, with no available treatments to enhance the effectiveness of regeneration. Using knock-out and transgenic overexpressor mice, we previously reported that BACE1, an aspartyl protease, as reported by Hemming et al. (PLoS One 4:12, 2009), negatively regulates peripheral nerve regeneration. Here, we investigated whether pharmacological inhibition of BACE may enhance peripheral nerve repair following traumatic nerve injury or neurodegenerative disease. BACE inhibitor-treated mice had increased numbers of regenerating axons and enhanced functional recovery after a sciatic nerve crush while inhibition increased axonal sprouting following a partial nerve injury. In the SOD1G93A ALS mouse model, BACE inhibition increased axonal regeneration with improved muscle re-innervation. CHL1, a BACE1 substrate, was elevated in treated mice and may mediate enhanced regeneration. Our data demonstrates that pharmacological BACE inhibition accelerates peripheral axon regeneration after varied nerve injuries and could be used as a potential therapy.
Tài liệu tham khảo
Gordon T. Nerve regeneration in the peripheral and central nervous systems. J Physiol, 594(13), 3517–3520 (2016).
Scheib J, Hoke A. Advances in peripheral nerve regeneration. Nat Rev Neurol, 9(12), 668–676 (2013).
Griffin JW, Pan B, Polley MA, Hoffman PN, Farah MH. Measuring nerve regeneration in the mouse. Exp Neurol, 223(1), 60–71 (2010).
Palispis WA, Gupta R. Surgical repair in humans after traumatic nerve injury provides limited functional neural regeneration in adults. Exp Neurol, 290, 106–114 (2017).
Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One, 4(12), e8477 (2009).
Sinha S, Anderson JP, Barbour R et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature, 402(6761), 537–540 (1999).
Vassar R, Bennett BD, Babu-Khan S et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286(5440), 735–741 (1999).
Yan R, Bienkowski MJ, Shuck ME et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature, 402(6761), 533–537 (1999).
Hu X, Hicks CW, He W et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci, 9(12), 1520–1525 (2006).
Willem M, Garratt AN, Novak B et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science, 314(5799), 664–666 (2006).
Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem, 282(16), 11982–11995 (2007).
Zhou L, Barão S, Laga M et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem, 287(31), 25927–25940 (2012).
Pigoni M, Wanngren J, Kuhn PH et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener, 11(1), 67 (2016).
Michailov GV, Sereda MW, Brinkmann BG et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science, 304(5671), 700–703 (2004).
Taveggia C, Zanazzi G, Petrylak A et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron, 47(5), 681–694 (2005).
Farah MH, Pan BH, Hoffman PN et al. Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci, 31(15), 5744–5754 (2011).
Tallon C, Rockenstein E, Masliah E, Farah MH. Increased BACE1 activity inhibits peripheral nerve regeneration after injury. Neurobiol Dis, 106, 147–157 (2017).
Chaisuksunt V, Campbell G, Zhang Y, Schachner M, Lieberman AR, Anderson PN. The cell recognition molecule CHL1 is strongly upregulated by injured and regenerating thalamic neurons. J Comp Neurol, 425(3), 382–392 (2000).
Zhang Y, Roslan R, Lang D, Schachner M, Lieberman AR, Anderson PN. Expression of CHL1 and L1 by neurons and glia following sciatic nerve and dorsal root injury. Mol Cell Neurosci, 16(1), 71–86 (2000).
Hinkle CL, Diestel S, Lieberman J, Maness PF. Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). J Neurobiol, 66(12), 1378–1395 (2006).
Barão S, Gärtner A, Leyva-Díaz E et al. Antagonistic Effects of BACE1 and APH1B-γ-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse. Cell Rep, 12(9), 1367–1376 (2015).
Kennedy ME, Stamford AW, Chen X et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med, 8(363), 363ra150 (2016).
Egan MF, Kost J, Voss T et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med, 380(15), 1408–1420 (2019).
Pan B, Grunewald B, Nguyen T et al. The lateral thoracic nerve and the cutaneous maximus muscle--a novel in vivo model system for nerve degeneration and regeneration studies. Exp Neurol, 236(1), 6–18 (2012).
Hegedus J, Putman CT, Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis, 28(2), 154–164 (2007).
Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci, 9(3), 408–419 (2006).
Schaefer AM, Sanes JR, Lichtman JW. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J Comp Neurol, 490(3), 209–219 (2005).
Fischer LR, Culver DG, Tennant P et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol, 185(2), 232–240 (2004).
Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci, 20(7), 2534–2542 (2000).
Azzouz M, Leclerc N, Gurney M, Warter JM, Poindron P, Borg J. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve, 20(1), 45–51 (1997).
Tallon C, Russell KA, Sakhalkar S, Andrapallayal N, Farah MH. Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. Neuroscience, 312, 179–189 (2016).
Bame M, Pentiak PA, Needleman R, Brusilow WSA. Effect of Sex on Lifespan, Disease Progression, and the Response to Methionine Sulfoximine in the SOD1 G93A Mouse Model for ALS. Gender Medicine, 9(6), 524–535 (2012).
May PC, Willis BA, Lowe SL et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci, 35(3), 1199–1210 (2015).
Stamford AW, Scott JD, Li SW et al. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. ACS Med Chem Lett, 3(11), 897–902 (2012).
Mandal M, Wu Y, Misiaszek J et al. Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. Journal of Medicinal Chemistry, 59(7), 3231–3248 (2016).
Feng G, Mellor RH, Bernstein M et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron, 28(1), 41–51 (2000).
Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264(5166), 1772–1775 (1994).
Cai H, Wang Y, McCarthy D et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci, 4(3), 233–234 (2001).
Scott JD, Li SW, Brunskill AP et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem, 59(23), 10435–10450 (2016).
Brown MC, Ironton R. Motor neurone sprouting induced by prolonged tetrodotoxin block of nerve action potentials. Nature, 265(5593), 459–460 (1977).
Pestronk A, Drachman D. Motor nerve sprouting and acetylcholine receptors. Science, 199(4334), 1223–1225 (1978).
Hu X, He W, Diaconu C et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. Faseb j, 22(8), 2970–2980 (2008).
Hu X, Hu J, Dai L, Trapp B, Yan R. Axonal and Schwann cell BACE1 is equally required for remyelination of peripheral nerves. J Neurosci, 35(9), 3806–3814 (2015).
Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci, 43(3), 470–477 (2011).
Eggers R, Tannemaat MR, De Winter F, Malessy MJ, Verhaagen J. Clinical and neurobiological advances in promoting regeneration of the ventral root avulsion lesion. Eur J Neurosci, 43(3), 318–335 (2016).
Gordon T, Amirjani N, Edwards DC, Chan KM. Brief post-surgical electrical stimulation accelerates axon regeneration and muscle reinnervation without affecting the functional measures in carpal tunnel syndrome patients. Exp Neurol, 223(1), 192–202 (2010).
Gordon T, Borschel GH. The use of the rat as a model for studying peripheral nerve regeneration and sprouting after complete and partial nerve injuries. Exp Neurol, 287(Pt 3), 331–347 (2017).
Gordon T, Hegedus J, Tam SL. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res, 26(2), 174–185 (2004).
Hoke A. Neuroprotection in the peripheral nervous system: rationale for more effective therapies. Arch Neurol, 63(12), 1681–1685 (2006).
Gordon T, Tyreman N, Raji MA. The basis for diminished functional recovery after delayed peripheral nerve repair. J Neurosci, 31(14), 5325–5334 (2011).
Sakuma M, Gorski G, Sheu S-H et al. Lack of motor recovery after prolonged denervation of the neuromuscular junction is not due to regenerative failure. European Journal of Neuroscience, 43(3), 451–462 (2016).
Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 457(7232), 981–989 (2009).
Bryson JB, Hobbs C, Parsons MJ et al. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Hum Mol Genet, 21(17), 3871–3882 (2012).
Seijffers R, Zhang J, Matthews JC et al. ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation. Proc Natl Acad Sci U S A, 111(4), 1622–1627 (2014).
Mancuso R, Martinez-Muriana A, Leiva T et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation. Neurobiol Dis, 95, 168–178 (2016).
Kataria H, Alizadeh A, Karimi-Abdolrezaee S. Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Prog Neurobiol, 101643 (2019).
Udina E, Putman CT, Harris LR, Tyreman N, Cook VE, Gordon T. Compensatory axon sprouting for very slow axonal die-back in a transgenic model of spinal muscular atrophy type III. J Physiol, 595(5), 1815–1829 (2017).
Joshi AR, Bobylev I, Zhang G, Sheikh KA, Lehmann HC. Inhibition of Rho-kinase differentially affects axon regeneration of peripheral motor and sensory nerves. Exp Neurol, 263, 28–38 (2015).
Joshi AR, Muke I, Bobylev I, Lehmann HC. ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis. J Comp Neurol, (2019).
Bixby JL, Lilien J, Reichardt LF. Identification of the major proteins that promote neuronal process outgrowth on Schwann cells in vitro. J Cell Biol, 107(1), 353–361 (1988).
Seilheimer B, Schachner M. Studies of adhesion molecules mediating interactions between cells of peripheral nervous system indicate a major role for L1 in mediating sensory neuron growth on Schwann cells in culture. J Cell Biol, 107(1), 341–351 (1988).